A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-061
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 27 Jan 2017 This trial has been completed in Finland.
- 24 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2017.